ActivBiotics To Present Results Of Pivotal Study In The Treatment Of Peripheral Arterial Disease At AHA Meeting

ActivBiotics, Inc. announced that the results of its pivotal clinical trial (PROVIDENCE-1) studying the effect of rifalazil in the treatment of intermittent claudication associated with peripheral arterial disease (PAD) will be presented on November 7, 2007 at 11:45 a.m. EST at a late breaker Scientific Session at the American Heart Association’s 2007 annual meeting being held in Orlando, Florida. Michael R. [click link for full article]

More: continued here

Filed under: Cardiovascular on October 25th, 2007